Development of a simple kit-based method for preparation of pharmaceutical-grade 68Ga-DOTATOC

Nuclear Medicine Communications

Volumn 36, Issue 5, 2015, Pages 502-510

  Asti, Mattia ^a   Iori, Michele ^a   Capponi, Pier Cesare ^a   Rubagotti, Sara ^a   Fraternali, Alessandro ^a   Versari, Annibale ^a  

^a S MARIA NUOVA HOSPITAL   (Italy)

Author keywords

DOTATOC; Gallium 68; Kit based synthesis; PET; Somatostatin analogues

Indexed keywords

ASCORBIC ACID; BUFFER; DOTATOC GA 68; SCAVENGER; TRACER; UNCLASSIFIED DRUG; GA(III)-DOTATOC; OCTREOTIDE; ORGANOMETALLIC COMPOUND; RADIOPHARMACEUTICAL AGENT;

ARTICLE; DRUG SYNTHESIS; EUROPEAN; FEASIBILITY STUDY; GENERATOR; HUMAN; ISOTOPE LABELING; MEDICAL LITERATURE; QUALITY CONTROL; RADIOCHEMISTRY; ANALOGS AND DERIVATIVES; CHEMISTRY; PROCEDURES; SYNTHESIS;

ISOTOPE LABELING; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; QUALITY CONTROL; RADIOCHEMISTRY; RADIOPHARMACEUTICALS;

EID: 84927519613     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0000000000000275     Document Type: Article

References (25)

1. Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, et al. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer 2010; 17:53-73.
2. Breeman WA, de Blois E, Sze Chan H, Konijnenberg M, Kwekkeboom DJ, Krenning EP. (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives. Semin Nucl Med 2011; 41:314-321.
3. Fani M, Maecke HR, Okarvi SM. Radiolabeled peptides: valuable tools for the detection and treatment of cancer. Theranostics 2012; 2:481-501.
4. 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2007; 34:1617-1626.
5. 68Ga-DOTATATE PET/CT, 99mTc-HYNIC-octreotide SPECT/CT, and whole-body MR imaging in detection of neuroendocrine tumors: a prospective trial. J Nucl Med 2014; 55:1598-1604.
6. Al-Nahhas A, Win Z, Szyszko T, Singh A, Nanni C, Fanti S, Rubello D. Gallium-68 PET: a new frontier in receptor cancer imaging. Anticancer Res 2007; 27 (6B):4087-4094.
7. 68Ga-PET: a powerful generator-based alternative to cyclotron-based PET radiopharmaceuticals. Contrast Media Mol Imaging 2008; 3:67-77.
8. Burke BP, Clemente GS, Archibald SJ. Recent advances in chelator design and labelling methodology for (68)Ga radiopharmaceuticals. J Labelled Comp Radiopharm 2014; 57:239-243.
9. 68Ga-somatostatin antagonists: the chelate makes the difference. J Nucl Med 2011; 52:1110-1118.
10. Asti M, Iori M, Capponi PC, Atti G, Rubagotti S, Martin R, et al. Influence of different chelators on the radiochemical properties of a 68-gallium labelled bombesin analogue. Nucl Med Biol 2014; 41:24-35.
11. 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med 2011; 52:1864-1870.
12. 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med 2013; 54:364-372.
13. 68Ga) edotreotide for injection. Eur Pharmacopeia 80 2013; 2482:1062.
14. 68Ga. Eur J Nucl Med Mol Imaging 2005; 32:478-485.
15. 68Ga for medical application. J Nucl Med 2007; 48:1741-1748.
16. 68Ga radiopharmaceuticals in high radiochemical purity. Bioconj Chem 2012; 23:1712-1717.
17. 68Ga-labelled peptides. Nucl Med Commun 2007; 28:870-875.
18. 68Ga-r-BHD) and assessment of its pharmaceutical quality for clinical use. Nucl Med Commun 2012; 33:1179-1187.
19. Chakrabarti MC, Le N, Paik CH, De Graff WG, Carrasquillo JA. Prevention of radiolysis of monoclonal antibody during labelling. J Nucl Med 1996; 37:1384-1388.
20. 68Ga-DOTATOC PET/CT and contrast-enhanced MRI. Eur J Nucl Med Mol Imaging 2012; 39:1409-1415.
21. 68Ga]DOTATOC-PET/CT in differentiating typical and atypical pulmonary carcinoids. Cancer Imaging 2011; 15:70-75.
22. Versari A, Sollini M, Frasoldati A, Fraternali A, Filice A, Froio A, et al. Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients. Thyroid 2014; 24:715-726.
23. 68Ga with different bifunctional chelators. Nucl Med Biol 2013; 40:197-205.
24. 68Ga-DOTA-TATE. Appl Radiat Isot 2013; 76:63-69.
25. 68Ga-bioconjugates with high specific radioactivity. Bioconj Chem 2004; 15:554-560.